{
    "clinical_study": {
        "@rank": "19878", 
        "acronym": "MV130", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The subjects will receive daily dose of the biological vaccine during 6 months"
            }, 
            {
                "arm_group_label": "Biological vaccine", 
                "arm_group_type": "Experimental", 
                "description": "The subjects will receive daily dose of the biological vaccine during 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the efficacy of a biological vaccine to prevent\n      episodes of bronchospasm, induced by recurrent respiratory tract infections, in children,\n      compared with a placebo group."
        }, 
        "brief_title": "Efficacy and Safety Evaluation in Recurrent Bronchospasms", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Bronchospasm", 
        "condition_browse": {
            "mesh_term": "Bronchial Spasm"
        }, 
        "detailed_description": {
            "textblock": "Double blind parallel placebo controlled study. The subjects will receive medication during\n      6 months and will be followed up during another six months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects whose parents /legal representative have given written informed consent.\n\n          -  Both gender\n\n          -  Subject up to 36 months of age.\n\n          -  Subjects with recurrent bronchospasms ; 3 or more exacerbations in the last 12 months\n\n        Exclusion Criteria:\n\n          -  Subjects whose parents/legal representative have not given written informed consent.\n\n          -  Subjects out of aged range\n\n          -  Subjects with malignancies or chemotherapy treatment\n\n          -  Subjects included in another clinical trial in the last 12 months.\n\n          -  Subject in immunosuppressive or immunostimulatory treatment\n\n          -  Subjects who have received iv gamma globulin in the past 12 months.\n\n          -  Subjects diagnosed with candidiasis or fungal recurrent infections.\n\n          -  Subjects diagnosed with malabsorption syndrome\n\n          -  Subjects with clinical allergy to common aeroallergens in the geographical area.\n\n          -  Subjects with hepatitis virus infections, HIV and tuberculosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "36 Months", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734811", 
            "org_study_id": "MV130-SLG-002", 
            "secondary_id": "2012-002450-24"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "Biological vaccine"
            ], 
            "description": "Daily dose", 
            "intervention_name": "Biological vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vaccine", 
            "Bronchospasm"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Manises", 
                        "country": "Spain", 
                        "state": "Valencia", 
                        "zip": "46940"
                    }, 
                    "name": "Hospital de Manises"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "nieto_ant@gva.es", 
                    "last_name": "Antonio Nieto, PhD; MD", 
                    "phone": "34961244378"
                }, 
                "contact_backup": {
                    "email": "mcasanovas@inmunotek.com", 
                    "last_name": "Miguel Casanovas, PhD; MD", 
                    "phone": "34916510010"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital Universitario y Polit\u00e9cnico La Fe"
                }, 
                "investigator": {
                    "last_name": "Antonio Nieto, PhD; MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Double-blind Placebo-controlled, Parallel, Single Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm for the Evaluation of Efficacy, Security and Clinical Impact.", 
        "overall_contact": {
            "email": "nieto_ant@gva.es", 
            "last_name": "Antonio Nieto, PhD; MD", 
            "phone": "34961244378"
        }, 
        "overall_contact_backup": {
            "email": "mcasanovas@inmunotek.com", 
            "last_name": "Miguel Casanovas, PhD; MD", 
            "phone": "34916510010"
        }, 
        "overall_official": {
            "last_name": "Miguel Casanovas, PhD; MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reduction in the number of bronchospasms episodes compared with previous year", 
            "measure": "Recurrent bronchospasm", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734811"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Shortening of the severity of the bronchospasm episodes", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Medication consumption", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Counting the: unscheduled visits to health center, emergency service visits, days of hospitalization and cost thereof, complementary tests, phone calls to the doctor or pediatrician per patient", 
                "measure": "Direct costs", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Counting the: absenteeism from nursery, caregivers to the child at home and during hospital admissions per patient.", 
                "measure": "Indirect costs", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Inmunotek S.L.", 
        "sponsors": {
            "collaborator": {
                "agency": "Unidad de Investigacion Medica en Epidemiologia Clinica", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Inmunotek S.L.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}